Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial

Tokyo, Japan and Cambridge, UK,06 November 2023 – Sosei Group Corporation has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial.

Scroll to Top